Literature DB >> 17457919

Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.

Takeshi Ichinohe1, Noriyo Nagata, Peter Strong, Shin-ichi Tamura, Hidehiro Takahashi, Ai Ninomiya, Masaki Imai, Takato Odagiri, Masato Tashiro, Hirofumi Sawa, Joe Chiba, Takeshi Kurata, Tetsutaro Sata, Hideki Hasegawa.   

Abstract

Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-alpha. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactic treatment with chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457919     DOI: 10.1002/jmv.20837

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

Review 1.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

2.  Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm.

Authors:  Rui Li; Annabelle Lim; Meng Chee Phoon; Teluguakula Narasaraju; Jowin K W Ng; Wee Peng Poh; Meng Kwoon Sim; Vincent T Chow; Camille Locht; Sylvie Alonso
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

3.  Fabrication of magnetic and fluorescent chitin and dibutyrylchitin sub-micron particles by oil-in-water emulsification.

Authors:  Barbara Blanco-Fernandez; Shatadru Chakravarty; Michael K Nkansah; Erik M Shapiro
Journal:  Acta Biomater       Date:  2016-09-01       Impact factor: 8.947

Review 4.  H5N1 pathogenesis studies in mammalian models.

Authors:  Jessica A Belser; Terrence M Tumpey
Journal:  Virus Res       Date:  2013-02-28       Impact factor: 3.303

Review 5.  Innate sensors of influenza virus: clues to developing better intranasal vaccines.

Authors:  Takeshi Ichinohe; Akiko Iwasaki; Hideki Hasegawa
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

6.  Intranasal administration of immunogenic poly-epitope from influenza H1N1 and H3N2 viruses adjuvanted with chitin and chitosan microparticles in BALB/c mice.

Authors:  Sahar Sadeghi; Mojgan Bandehpour; Mostafa Haji Molla Hoseini; Zarin Sharifnia
Journal:  Iran J Basic Med Sci       Date:  2021-08       Impact factor: 2.699

7.  Efficacy of intranasal administration of a modified live feline herpesvirus 1 and feline calicivirus vaccine against disease caused by Bordetella bronchiseptica after experimental challenge.

Authors:  A Bradley; J Kinyon; T Frana; D Bolte; D R Hyatt; M R Lappin
Journal:  J Vet Intern Med       Date:  2012-08-03       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.